{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:16:23Z","timestamp":1762870583227,"version":"build-2065373602"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00393-025-01724-x","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T08:25:58Z","timestamp":1759307158000},"page":"717-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management von osteologischen und renalen Komorbidit\u00e4ten bei rheumatologischen Erkrankungen","Management of osteologic and renal comorbidities in patients with rheumatic diseases"],"prefix":"10.1007","volume":"84","author":[{"given":"A.","family":"Schatz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Xanthouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Triantafyllias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bergner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"1724_CR1","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00393-021-01028-w","volume":"80","author":"J Leipe","year":"2021","unstructured":"Leipe J, Holle JU, Weseloh C, Pfeil A, Kr\u00fcger K; die Kommission Pharmakotherapie der Deutschen Gesellschaft f\u00fcr Rheumatologie e.\u202fV. (DGRh). Empfehlungen der Deutschen Gesellschaft f\u00fcr Rheumatologie zum Management der Glukokortikoid-induzierten Osteoporose [German Society of Rheumatology Recommendations for the management of glucocorticoid-induced Osteoporosis. German version]. Z Rheumatol. 2021 Sep;80(7):670-687. German. doi: 10.1007\/s00393-021-01028-w. Epub 2021 Aug 6. Erratum in: Z Rheumatol. 2022 Apr;81(3):263. doi: 10.1007\/s00393-022-01195-4. PMID: 34357436.","journal-title":"Z Rheumatol"},{"issue":"1","key":"1724_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis\u00a0JA, Norton\u00a0N, Harvey\u00a0NC, Jacobson\u00a0T, Johansson\u00a0H, Lorentzon\u00a0M, McCloskey\u00a0EV, Willers\u00a0C, Borgstr\u00f6m\u00a0F (2021) SCOPE 2021: a\u00a0new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"key":"1724_CR3","unstructured":"(2023) Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.\u202fV. Prophylaxe, Diagnostik und Therapie der Osteoporose; Langfassung V 2.1; AWMF-Register-Nr.: 183\/001. https:\/\/register.awmf.org\/assets\/guidelines\/183-001l_S3_Prophylaxe-Diagnostik-Therapie-der-Osteoporose_2023-11.pdf"},{"issue":"1","key":"1724_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11657-018-0510-0","volume":"13","author":"JA Kanis","year":"2018","unstructured":"Kanis\u00a0JA, Johansson\u00a0H, Harvey\u00a0NC, McCloskey\u00a0EV (2018) A\u00a0brief history of FRAX. Arch Osteoporos 13(1):118. https:\/\/doi.org\/10.1007\/s11657-018-0510-0","journal-title":"Arch Osteoporos"},{"key":"1724_CR5","unstructured":"Dachverband Osteologie S3-Leitlinie: K\u00f6rperliches Training zur Frakturprophylaxe, Version 11.02.2025. https:\/\/register.awmf.org\/assets\/guidelines\/183-002m_S3_Training_Frakturprophylaxe_2025-02.pdf"},{"issue":"8","key":"1724_CR6","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/jbmr.2216","volume":"29","author":"C Muschitz","year":"2014","unstructured":"Muschitz\u00a0C, Kocijan\u00a0R, Fahrleitner-Pammer\u00a0A, Pavo\u00a0I, Haschka\u00a0J, Schima\u00a0W, Kapiotis\u00a0S, Resch\u00a0H (2014) Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density\u2014the CONFORS Study. J\u00a0Bone Miner Res 29(8):1777\u20131785. https:\/\/doi.org\/10.1002\/jbmr.2216","journal-title":"J Bone Miner Res"},{"issue":"9999","key":"1724_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder\u00a0BZ, Tsai\u00a0JN, Uihlein\u00a0AV, Wallace\u00a0PM, Lee\u00a0H, Neer\u00a0RM, Burnett-Bowie\u00a0SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a\u00a0randomised controlled trial. Lancet 386(9999):1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"issue":"9","key":"1724_CR8","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","volume":"35","author":"S Kumar","year":"2024","unstructured":"Kumar\u00a0S, Gild\u00a0ML, McDonald\u00a0MM, Kim\u00a0AS, Clifton-Bligh\u00a0RJ, Girgis\u00a0CM (2024) A\u00a0novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. Osteoporos Int 35(9):1669\u20131675. https:\/\/doi.org\/10.1007\/s00198-024-07139-9","journal-title":"Osteoporos Int"},{"issue":"5","key":"1724_CR9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s00108-021-00993-3","volume":"62","author":"B Obermayer-Pietsch","year":"2021","unstructured":"Obermayer-Pietsch\u00a0B, F\u00f6ssl\u00a0I, Dimai\u00a0HP (2021) Langfristige Therapiekonzepte bei Osteoporose [Long-term treatment concepts for osteoporosis]. Internist 62(5):474\u2013485. https:\/\/doi.org\/10.1007\/s00108-021-00993-3","journal-title":"Internist"},{"issue":"2","key":"1724_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jbmr.4188","volume":"36","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan\u00a0A, Midkiff\u00a0K, Harris\u00a0D, Kellier-Steele\u00a0N, McSorley\u00a0D, Andrews\u00a0EB (2021) Teriparatide did not increase adult osteosarcoma incidence in a\u00a015-year US postmarketing surveillance study. J\u00a0Bone Miner Res 36(2):244\u2013251. https:\/\/doi.org\/10.1002\/jbmr.4188","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1724_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5435\/JAAOS-D-22-01094","volume":"31","author":"CL McDonald","year":"2023","unstructured":"McDonald\u00a0CL, Johnson\u00a0K, Alsoof\u00a0D, Molino\u00a0J, Balmaceno-Criss\u00a0M, Daniels\u00a0AH (2023) Treatment of osteoporosis with anabolic agents and the risk of primary bone cancers: a\u00a0study of 44,728 patients treated with Teriparatide and Abaloparatide. J\u00a0Am Acad Orthop Surg 31(10):520\u2013528. https:\/\/doi.org\/10.5435\/JAAOS-D-22-01094","journal-title":"J Am Acad Orthop Surg"},{"key":"1724_CR12","unstructured":"Schiegnitz E, Al-Nawas B, Hoefert S, Otto S, Pautke C, Ristow O, Voss P, Gr\u00f6tz KA S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen, AWMF Registernummer: 007\u2013091. https:\/\/register.awmf.org\/assets\/guidelines\/007-091l_S3_Antiresorptiva-assoziierte-Kiefernekrosen-AR-ONJ_2018-12-abgelaufen.pdf"},{"issue":"16","key":"1724_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman\u00a0F, Crittenden\u00a0DB, Adachi\u00a0JD, Binkley\u00a0N, Czerwinski\u00a0E, Ferrari\u00a0S, Hofbauer\u00a0LC, Lau\u00a0E, Lewiecki\u00a0EM, Miyauchi\u00a0A, Zerbini\u00a0CA, Milmont\u00a0CE, Chen\u00a0L, Maddox\u00a0J, Meisner\u00a0PD, Libanati\u00a0C, Grauer\u00a0A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N\u00a0Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"10225","key":"1724_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a\u00a0systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709\u2013733. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"issue":"12","key":"1724_CR15","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/ndt\/gfw315","volume":"32","author":"T Tokoroyama","year":"2017","unstructured":"Tokoroyama\u00a0T, Ando\u00a0M, Setoguchi\u00a0K, Tsuchiya\u00a0K, Nitta\u00a0K (2017) Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a\u00a0large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant 32(12):2035\u20132042. https:\/\/doi.org\/10.1093\/ndt\/gfw315","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"1724_CR16","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s10067-017-3804-5","volume":"36","author":"S Mori","year":"2017","unstructured":"Mori\u00a0S, Yoshitama\u00a0T, Hirakata\u00a0N, Ueki\u00a0Y (2017) Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a\u00a0cross-sectional study in community hospitals. Clin Rheumatol 36(12):2673\u20132682. https:\/\/doi.org\/10.1007\/s10067-017-3804-5","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1724_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00393-022-01308","volume":"82","author":"C Fiehn","year":"2023","unstructured":"Fiehn\u00a0C, Leipe\u00a0J, Weseloh\u00a0C, Bergner\u00a0R, Kr\u00fcger\u00a0K (2023) Assessment of interactions and dosage recommendations of synthetic DMARDs-Evidence-based and consensus-based recommendations based on a\u00a0systematic literature search. Z\u00a0Rheumatol 82(2):151\u2013162. https:\/\/doi.org\/10.1007\/s00393-022-01308","journal-title":"Z Rheumatol"},{"issue":"2","key":"1724_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/ard-2024-226156","volume":"84","author":"S Fukui","year":"2025","unstructured":"Fukui\u00a0S, Winkelmayer\u00a0WC, Tedeschi\u00a0SK, Marrugo\u00a0J, Hongshu\u00a0G, Harrold\u00a0L, Litman\u00a0HJ, Shinozaki\u00a0T, Solomon\u00a0DH (2025) Disease activity of rheumatoid arthritis and kidney function decline: a\u00a0large prospective registry study. Ann Rheum Dis 84(2):201\u201329. https:\/\/doi.org\/10.1136\/ard-2024-226156","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1724_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4081\/reumatismo.2018.1064","volume":"70","author":"F Saccon","year":"2018","unstructured":"Saccon\u00a0F, Gatto\u00a0M, Larosa\u00a0M, Ometto\u00a0F, Felicetti\u00a0M, Padoan\u00a0R, Zen\u00a0M (2018) Diagnostic and prognostic role of renal histopathology in rheumatic diseases. Reumatismo 70(3):165\u2013177. https:\/\/doi.org\/10.4081\/reumatismo.2018.1064","journal-title":"Reumatismo"},{"issue":"1","key":"1724_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00393-005-0700-1","volume":"64","author":"A Schwarting","year":"2005","unstructured":"Schwarting\u00a0A, M\u00e4rker-Hermann\u00a0E (2005) Renal manifestations of rheumatic diseases. Z\u00a0Rheumatol 64(1):18\u201325. https:\/\/doi.org\/10.1007\/s00393-005-0700-1","journal-title":"Z Rheumatol"},{"issue":"1","key":"1724_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ndt\/gfad154","volume":"39","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera\u00a0JE, Bakkaloglu\u00a0SA, Bolignano\u00a0D, Nistor\u00a0I, Sarafidis\u00a0PA, Stoumpos\u00a0S, Cozzolino\u00a0MG, Ortiz\u00a0A (2023) Chronic kidney disease: the missing concept in the 2019 EULAR\/ERA-EDTA recommendations for lupus nephritis. Nephrol Dial Transplant 39(1):151\u2013158. https:\/\/doi.org\/10.1093\/ndt\/gfad154","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1724_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","volume":"94","author":"M De Rosa","year":"2018","unstructured":"De Rosa\u00a0M, Azzato\u00a0F, Toblli\u00a0JE, De Rosa\u00a0G, Fuentes\u00a0F, Nagaraja\u00a0HN, Nash\u00a0R, Rovin\u00a0BH (2018) A\u00a0prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94(4):788\u2013794. https:\/\/doi.org\/10.1016\/j.kint.2018.05.021","journal-title":"Kidney Int"},{"issue":"6","key":"1724_CR23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/0961203321995251","volume":"30","author":"U Das","year":"2021","unstructured":"Das\u00a0U, Patel\u00a0R, Guditi\u00a0S, Taduri\u00a0G (2021) Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis. Lupus 30(6):876\u2013883. https:\/\/doi.org\/10.1177\/0961203321995251","journal-title":"Lupus"},{"key":"1724_CR24","doi-asserted-by":"publisher","first-page":"107121","DOI":"10.1016\/j.rmed.2023.107121","volume":"209","author":"R Bergner","year":"2023","unstructured":"Bergner\u00a0R, Weiner\u00a0SM, Kehl\u00a0G, de Groot\u00a0K, Tielke\u00a0S, Asendorf\u00a0T, Korsten\u00a0P (2023) Renal disease in sarcoidosis patients in a\u00a0German multicentric retrospective cohort study. Respir Med 209:107121. https:\/\/doi.org\/10.1016\/j.rmed.2023.107121","journal-title":"Respir Med"},{"issue":"12","key":"1724_CR25","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/ndt\/16.12.2328","volume":"16","author":"N Bossini","year":"2001","unstructured":"Bossini\u00a0N, Savoldi\u00a0S, Franceschini\u00a0F, Mombelloni\u00a0S, Baronio\u00a0M, Cavazzana\u00a0I, Viola\u00a0BF, Valzorio\u00a0B, Mazzucchelli\u00a0C, Cattaneo\u00a0R, Scolari\u00a0F, Maiorca\u00a0R (2001) Clinical and morphological features of kidney involvement in primary Sj\u00f6gren\u2019s syndrome. Nephrol Dial Transplant 16(12):2328\u20132336. https:\/\/doi.org\/10.1093\/ndt\/16.12.2328","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"1724_CR26","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","volume":"54","author":"M Ramos-Casals","year":"2015","unstructured":"Ramos-Casals\u00a0M, Brito-Zer\u00f3n\u00a0P, Seror\u00a0R, Bootsma\u00a0H, Bowman\u00a0SJ, D\u00f6rner\u00a0T, Gottenberg\u00a0J\u2011E, Mariette\u00a0X, Theander\u00a0E, Stefano Bombardieri De Vita\u00a0S, Mandl\u00a0T, Ng\u00a0W\u2011F, Kruize\u00a0A, Tzioufas\u00a0ACV (2015) Characterization of systemic disease in primary Sj\u00f6gren\u2019s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 54(12):2230\u20132238. https:\/\/doi.org\/10.1093\/rheumatology\/kev200 (EULAR Sj\u00f6gren Syndrome Task Force)","journal-title":"Rheumatology"},{"key":"1724_CR27","unstructured":"KDIGO-Leitlinien. https:\/\/kdigo.org\/wp-content\/uploads\/2024\/03\/KDIGO-2024-CKD-Guideline.pdf"},{"issue":"15","key":"1724_CR28","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0F\u2011F, Mann\u00a0JFE, McMurray\u00a0JJV, Lindberg\u00a0M, Rossing\u00a0P, Sj\u00f6str\u00f6m\u00a0CD, Toto\u00a0RD, Langkilde\u00a0A\u2011M, Wheeler\u00a0DC (2020) DAPA-CKD trial committees and investigators Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"2","key":"1724_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington\u00a0WG, Staplin\u00a0N, Wanner\u00a0C, Green\u00a0JB, Hauske\u00a0SJ, Emberson\u00a0JR, Preiss\u00a0D, Judge\u00a0P, Mayne\u00a0KJ, Ng\u00a0SYA, Sammons\u00a0E, Zhu\u00a0D, Hill\u00a0M, Stevens\u00a0W, Wallendszus\u00a0K, Brenner\u00a0S, Cheung\u00a0AK, Liu\u00a0Z\u2011H, Li\u00a0J, Hooi\u00a0LS, Liu\u00a0W, Kadowaki\u00a0T, Nangaku\u00a0M, Adeera\u00a0L, Cherney\u00a0D, Maggioni\u00a0AP, Pontremoli\u00a0R, Rajat\u00a0D, Goto\u00a0S, Rossello\u00a0X, Tuttle\u00a0KR, Steubl\u00a0D, Petrini\u00a0M, Massey\u00a0D, Eilbracht\u00a0J, Brueckmann\u00a0M, Landray\u00a0MJ, Baigent\u00a0C, Haynes\u00a0R (2023) Empagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"issue":"8","key":"1724_CR30","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O, Fransen\u00a0J, Avouac\u00a0J, Becker\u00a0M, Kulak\u00a0A, Allanore\u00a0Y, Distler\u00a0O, Clements\u00a0P, Cutolo\u00a0M, Czirjak\u00a0L, Damjanov\u00a0N, Del Galdo\u00a0F, Denton\u00a0CP, Distler\u00a0JHW, Foeldvari\u00a0I, Figelstone\u00a0K, Frerix\u00a0M, Furst\u00a0DE, Guiducci\u00a0S, Hunzelmann\u00a0N, Khanna\u00a0D, Matucci-Cerinic\u00a0M, Herrick\u00a0AL, van den Hoogen\u00a0F, van Laar\u00a0JM, Riemekasten\u00a0G, Silver\u00a0R, Smith\u00a0V, Sulli\u00a0A, Tarner\u00a0I, Tyndall\u00a0A, Welling\u00a0J, Wigley\u00a0F, Valentini\u00a0G, Walker\u00a0UA, Zulian\u00a0F, M\u00fcller-Ladner\u00a0U (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909 (EUSTAR Coauthors)","journal-title":"Ann Rheum Dis"},{"key":"1724_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.05.009","author":"Y Yu","year":"2025","unstructured":"Yu\u00a0Y, Biros\u00a0E, Chang\u00a0X, Mallett\u00a0AJ (2025) A\u00a0systematic review of treatment for acute interstitial nephritis. Kidney Int Rep. https:\/\/doi.org\/10.1016\/j.ekir.2025.05.009 (in press)","journal-title":"Kidney Int Rep"},{"issue":"Suppl1","key":"1724_CR32","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s00393-024-01597-6","volume":"84","author":"JU Holle","year":"2025","unstructured":"Holle\u00a0JU, Kubacki\u00a0T, Aries\u00a0P, Hellmich\u00a0B, Kernder\u00a0A, Kneitz\u00a0C, Lamprecht\u00a0P, Schirmer\u00a0JH, Schreiber\u00a0A, Berlit\u00a0P, Bley\u00a0TA, Bl\u00f6dt\u00a0S, Decker\u00a0L, de Groot\u00a0K, Engel\u00a0S, Jordans\u00a0I, Frye\u00a0B, Haubitz\u00a0M, Holl-Ulrich\u00a0K, K\u00f6tter\u00a0I, Laudien\u00a0M, Milger-Kneidinger\u00a0K, Muche Borowski\u00a0C, M\u00fcller-Ladner\u00a0U, Ne\u00df\u00a0T, N\u00f6lle\u00a0B, Reinhold-Keller\u00a0E, Ruffer\u00a0N, Scheuerm\u00a0K (2025) Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden (S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie e.\u202fV. (DGRh)). Z\u00a0Rheumatol 84(Suppl1):S1\u2013S49. https:\/\/doi.org\/10.1007\/s00393-024-01597-6","journal-title":"Z Rheumatol"},{"key":"1724_CR33","unstructured":"Mucke J, Anders H\u2011J, Aringer M, Berlit P, B\u00f6ltz S, Burchardi F\u2011C, D\u00f6rner T, Fischer-Betz R, Hoyer BF, Lorenz H\u2011M, Meder B, Miesbach W, Reuss-Borst M, Schanze S, Schwarting A, Seeliger B, Specker C, Tenbrock K, Voll R, Weinmann-Menke J, Witte T, Worm M, Bertsias G, Schneider M S3-Leitlinie Management des systemischen Lupus erythematodes mit sekund\u00e4rem Antiphospholipid-Syndrom, Kinderwunsch und Schwangerschaft. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/060-008"},{"issue":"4","key":"1724_CR34","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","volume":"94","author":"M De Rosa","year":"2018","unstructured":"De Rosa\u00a0M, Azzato\u00a0F, Toblli\u00a0JE, De Rosa\u00a0G, Fuentes\u00a0F, Nagaraja\u00a0HN, Nash\u00a0N, Rovin\u00a0BH (2018) A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94(4):788\u2013794. https:\/\/doi.org\/10.1016\/j.kint.2018.05.021","journal-title":"Kidney Int"},{"issue":"24","key":"1724_CR35","doi-asserted-by":"publisher","first-page":"e7099","DOI":"10.1097\/MD.0000000000007099","volume":"96","author":"J Narv\u00e1ez","year":"2017","unstructured":"Narv\u00e1ez\u00a0J, Ricse\u00a0M, Gom\u00e0\u00a0M, Mitjavila\u00a0F, Fulladosa\u00a0X, Capdevila\u00a0O, Torras\u00a0J, Juanola\u00a0X, Pujol-Farriols\u00a0R, Nolla\u00a0JM (2017) The value of repeat biopsy in lupus nephritis flares. Medicine 96(24):e7099. https:\/\/doi.org\/10.1097\/MD.0000000000007099","journal-title":"Medicine"},{"issue":"1","key":"1724_CR36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ndt\/gfae143","volume":"40","author":"J Friedrich","year":"2024","unstructured":"Friedrich\u00a0J, Bellmann\u00a0M, Klank\u00a0D, Porubsky\u00a0S, Bergner\u00a0R (2024) Clinical and histological comparison of IgA nephritis and renal IgA vasculitis. Nephrol Dial Transplant 40(1):182\u2013192. https:\/\/doi.org\/10.1093\/ndt\/gfae143","journal-title":"Nephrol Dial Transplant"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01724-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01724-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01724-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:06:22Z","timestamp":1762869982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01724-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01724-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"27 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die wissenschaftliche Leitung wurde korrigiert.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"A.\u00a0Schatz\n                      : A.\u00a0Finanzielle Interessen: A.\u00a0Schatz gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte \u00c4rztin, RZ Rheumazentrum Rheinland-Pfalz, Bad Kreuznach.\n                      P.\u00a0Xanthouli\n                      : A.\u00a0Finanzielle Interessen: Honorar: J&J, MSD, BI; Au\u00dferhalb dieser Arbeit.\u00a0\u2013 B. Nichtfinanzielle Interessen: Fach\u00e4rztin f\u00fcr Innere Medizin, Rheumatologie und Pneumologie, Thoraxklinik am Universit\u00e4tsklinikum Heidelberg, R\u00f6ntgenstr. 1, 69125 Heidelberg, Med. Klinik V, INF 410, 69120 Heidelberg | Mitgliedschaften: DGRh, DGK.\n                      K.\u00a0Triantafyllias\n                      : A.\u00a0Finanzielle Interessen: K.\u00a0Triantafyllias gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Leitender Oberarzt Akut-Rheumazentrum Rheinland Pfalz, 55543, Bad Kreuznach.\n                      R.\u00a0Bergner\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare: Abbvie, BMS, Chugai, Galapagos (Alphasigma), GSK, Johnson&Johnson, Lilly, MSD, Novartis, Vifor | .\u00a0\u2013 Advisoryboard: Abbvie, GSK, Vifor.\u00a0\u2013 B. Nichtfinanzielle Interessen: Chefarzt der Medizinischen Klinik A, Fachbereich Nephrologie\/Rheumatologie, Klinikum Ludwigshafen | Stellv. Sprecher der Kommission f\u00fcr studentische Ausbildung der Deutschen Gesellschaft f\u00fcr Rheumatologie und Immunologie (DGRh) | Mitglied im Vorstand der Arbeitsgemeinschaft f\u00fcr Rheumatologie Rheinland-Pfalz und Saarland; Mitglied im Beirat der Saarl\u00e4ndisch-Pf\u00e4lzischen Gesellschaft f\u00fcr Innere Medizin (SPIG); Mitglied in der Deutschen Gesellschaft f\u00fcr Rheumatologie und Immunologie; Mitglied und Ausbilder in der Deutschen Gesellschaft f\u00fcr Ultraschall in der Medizin (DEGUM); Mitglied in der Europ\u00e4ischen Vasculitis Studiengruppe (EUVAS).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}